Table of Contents (84 articles)

Alkylating anticancer agents and their relations to microRNAs

Bernhard Biersack

View Full-Text Download PDF Pages 1-17

Germline variants in cancer therapy

Meike Kaehler, Ingolf Cascorbi

View Full-Text Download PDF Pages 18-30

Influence of lysosomal sequestration on multidrug resistance in cancer cells

Reginald Halaby

View Full-Text Download PDF Pages 31-42

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development

Paolo Tarantino, ... Giuseppe Curigliano

View Full-Text Download PDF Pages 43-52

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

Gladys Olivera, ... Salvador F. Aliño

View Full-Text Download PDF Pages 53-68

Pharmacogenetics of anticancer monoclonal antibodies

Dmitrii Shek, ... Irina Piatkov

View Full-Text Download PDF Pages 69-81

Resistance to anti-tubulin agents: From vinca alkaloids to epothilones

Werner Krause

View Full-Text Download PDF Pages 82-106

Somatic pharmacogenomics of gastrointestinal stromal tumor

Gloria Ravegnini, ... Sabrina Angelini

View Full-Text Download PDF Pages 107-115

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines

Elena De Mattia, ... Erika Cecchin

View Full-Text Download PDF Pages 116-130

Imaging of hypoxia in human glioblastoma with dynamic 18F-fluoromisonidazole PET

Redha-Alla Abdo, ... M’hamed Bentourkia

View Full-Text Download PDF Pages 131-140

Drug resistance and combating drug resistance in cancer

Xuan Wang, ... Xiaozhuo Chen

View Full-Text Download PDF Pages 141-160

Emerging targets in cancer drug resistance

Shashank Kumar, ... Sanjay Gupta

View Full-Text Download PDF Pages 161-177

Mechanism of resistance to immune checkpoint inhibitors

Manu R. Pandey, Marc S. Ernstoff

View Full-Text Download PDF Pages 178-188

Molecular mechanisms of enzalutamide resistance in prostate cancer

Eliot B. Blatt, Ganesh V. Raj

View Full-Text Download PDF Pages 189-197

New insights into acquired endocrine resistance of breast cancer

Ping Fan, V. Craig Jordan

View Full-Text Download PDF Pages 198-209

Overcome cancer drug resistance by targeting epigenetic modifications of centrosome

Zan-Hui Jia, ... Hong Zhang

View Full-Text Download PDF Pages 210-224

Pharmacogenetic and pharmacogenomic discovery strategies

Concetta Crisafulli, ... Saverio Alberti

View Full-Text Download PDF Pages 225-241

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia

Rachid Abaji, Maja Krajinovic

View Full-Text Download PDF Pages 242-255

Pharmacogenetics of thiopurines

Raffaella Franca, ... Giuliana Decorti

View Full-Text Download PDF Pages 256-270

Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients

Heidi Schwarzenbach, Peter B. Gahan

View Full-Text Download PDF Pages 271-296

Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer

Logeswari Ponnusamy, ... Kamaleshwar P. Singh

View Full-Text Download PDF Pages 297-312

The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities

Lauren K. Meyer, Michelle L. Hermiston

View Full-Text Download PDF Pages 313-325

The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors

Jasmine Cassar White, ... Francesco Crea

View Full-Text Download PDF Pages 326-334

Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation

Akimasa Seno, ... Masaharu Seno

View Full-Text Download PDF Pages 335-350

Perspective: plasticity, the enemy of the good

Sarah Yvonnet, ... Alexandre E. Escargueil

View Full-Text Download PDF Pages 351-355

Glutaminase inhibition in renal cell carcinoma therapy

Aleksandra M. Raczka, Paul A. Reynolds

View Full-Text Download PDF Pages 356-364

Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

Matthew J. Sale, ... Simon J. Cook

View Full-Text Download PDF Pages 365-380

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Clélia Mathieu, ... Juliette Vergnaud-Gauduchon

View Full-Text Download PDF Pages 381-398

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer

Heidi Schwarzenbach, Peter B. Gahan

View Full-Text Download PDF Pages 399-418

Computational analyses for cancer biology based on exhaustive experimental backgrounds

Jun Koseki, ... Hideshi Ishii

View Full-Text Download PDF Pages 419-427

Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers

Nilay Shah

View Full-Text Download PDF Pages 428-446

Drug-adapted cancer cell lines as preclinical models of acquired resistance

Martin Michaelis, ... Jindrich Cinatl

View Full-Text Download PDF Pages 447-456

Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets

Takahiko Murayama, Noriko Gotoh

View Full-Text Download PDF Pages 457-470

Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein

Di Xia, ... Lothar Esser

View Full-Text Download PDF Pages 471-489

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies

Poornima Paramasivan, ... Yusuf Y. Deeni

View Full-Text Download PDF Pages 490-515

Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

Leonard C. Rogers, Brian A. Van Tine

View Full-Text Download PDF Pages 516-526

Insights into breast cancer phenotying through molecular omics approaches and therapy response

Jose E. Belizario, Angela F. Loggulo

View Full-Text Download PDF Pages 527-538

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines

Yukio Nishimura, Kazuyuki Itoh

View Full-Text Download PDF Pages 539-549

Long non-coding RNAs regulation of therapeutic resistance

Susan Tsang, ... Jason T. Yustein

View Full-Text Download PDF Pages 550-567

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy

David K. Lau, ... Andrew Weickhardt

View Full-Text Download PDF Pages 568-579

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Ratnakar Singh, ... Michael J. Spinella

View Full-Text Download PDF Pages 580-594

Mechanisms of resistance to anti-angiogenic treatments

Francesco Pezzella

View Full-Text Download PDF Pages 595-607

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

Angela Mweempwa, Michelle K. Wilson

View Full-Text Download PDF Pages 608-617

MicroRNAs and cancer drug resistance: over two thousand characters in search of a role

Bruno Costa Gomes, ... António Sebastião Rodrigues

View Full-Text Download PDF Pages 618-633

Mitochondrial determinants of chemoresistance

Ansooya Bokil, Patricia Sancho

View Full-Text Download PDF Pages 634-646

Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies

Blanca Scheijen

View Full-Text Download PDF Pages 647-664

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Pooja Murthy, Franco Muggia

View Full-Text Download PDF Pages 665-679

Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

Marta Alonso-Peña, ... Jose J.G. Marin

View Full-Text Download PDF Pages 680-709

Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators

Silvia Dei, ... Elisabetta Teodori

View Full-Text Download PDF Pages 710-743

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors

Sarah E. Fenton, ... Sunandana Chandra

View Full-Text Download PDF Pages 744-761

Role of circulating tumor cell spheroids in drug resistance

Gerhard Hamilton, Barbara Rath

View Full-Text Download PDF Pages 762-772

Stress and drug resistance in cancer

Renée L. Flaherty, ... Melanie S. Flint

View Full-Text Download PDF Pages 773-786

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase

Filippo Merloni, ... Rossana Berardi

View Full-Text Download PDF Pages 787-802

Targeting MYCN and ALK in resistant and relapsing neuroblastoma

Elizabeth R Tucker, ... Louis Chesler

View Full-Text Download PDF Pages 803-812

Targeting the “undruggable” RAS - new strategies - new hope?

Britta Mörchen, ... Iris Helfrich

View Full-Text Download PDF Pages 813-826

The effects of growth hormone on therapy resistance in cancer

Reetobrata Basu, John J. Kopchick

View Full-Text Download PDF Pages 827-846

The role of exosomal microRNAs; focus on clinical applications in breast cancer

Aiko Sueta, ... Hirotaka Iwase

View Full-Text Download PDF Pages 847-861

Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma

Cathy W. Levenson, ... Victor D. Schepkin

View Full-Text Download PDF Pages 862-876

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy

Miki Mori, ... Seigo Nakamura

View Full-Text Download PDF Pages 877-884

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

Torben Frøstrup Hansen, ... Anders Jakobsen

View Full-Text Download PDF Pages 885-896

Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance

Ana Armada, ... António Sebastião Rodrigues

View Full-Text Download PDF Pages 897-911

Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Mark Bowling, ... Paul Walker

View Full-Text Download PDF Pages 912-916

Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance

Andrea Bild, ... Michael Kahn

View Full-Text Download PDF Pages 917-932

Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1

Nira Ben-Jonathan, ... Eric R. Hugo

View Full-Text Download PDF Pages 933-947

Cancer stem cells in neuroblastoma therapy resistance

Natarajan Aravindan, ... Sheeja Aravindan

View Full-Text Download PDF Pages 948-967

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement

Fabiana Conciatori, ... Ludovica Ciuffreda

View Full-Text Download PDF Pages 968-979

Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies

Jesus Rodriguez-Pascual, ... Cristobal Belda-Iniesta

View Full-Text Download PDF Pages 980-993

Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs

William H. Gmeiner

View Full-Text Download PDF Pages 994-1001

Exosomal lncRNAs: the newest promising liquid biopsy

Marta Tellez-Gabriel, Dominique Heymann

View Full-Text Download PDF Pages 1002-1017

In search of effective therapies to overcome resistance to Temozolomide in brain tumours

Kaouthar Bouzinab, ... Tracey D. Bradshaw

View Full-Text Download PDF Pages 1018-1031

Kinase inhibitors: look beyond the label on the bottle

Paul Dent, ... John F. Hancock

View Full-Text Download PDF Pages 1032-1043

Liquid biopsies in myeloid malignancies

Bilal Abdulmawjood, ... Pedro V. Baptista

View Full-Text Download PDF Pages 1044-1061

Liquid biopsy in metastatic breast cancer

Malgorzata Banys-Paluchowski, Peter Paluchowski

View Full-Text Download PDF Pages 1062-1068

Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics

Muireann Ní Bhaoighill, Elaine A. Dunlop

View Full-Text Download PDF Pages 1069-1085

MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

Natarajan Aravindan, ... Sheeja Aravindan

View Full-Text Download PDF Pages 1086-1105

Network rewiring, adaptive resistance and combating strategies in breast cancer

Constance Gaya Cremers, Lan K. Nguyen

View Full-Text Download PDF Pages 1106-1126

Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence

Monica Angelica Amaya Padilla, ... Yu Yu

View Full-Text Download PDF Pages 1127-1135

RET in breast cancer: pathogenic implications and mechanisms of drug resistance

Cristiana Lo Nigro, ... Isabella Ceccherini

View Full-Text Download PDF Pages 1136-1152

Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts

Evan J. Brettrager, Robert C.A.M. van Waardenburg

View Full-Text Download PDF Pages 1153-1163

The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia

Lauren K. Meyer, Michelle L. Hermiston

View Full-Text Download PDF Pages 1164-1177

The role of exosomal long non-coding RNAs in cancer drug resistance

Mireia Cruz De los Santos, ... George A. Calin

View Full-Text Download PDF Pages 1178-1192

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways

Marissa Williams, ... Glen Reid

View Full-Text Download PDF Pages 1193-1206

Components of the human-specific, p53-mediated “kill switch” tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation

Jonathan Nyce

View Full-Text Download PDF Pages 1207-1214

Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer

Philip C. Miller, ... Marc E. Lippman

View Full-Text Download PDF Pages 1215-1223

Actions for 0 selected articles